Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

被引:1
|
作者
Chiang, Ting-Yu [1 ]
Hsu, Hung-Chih [2 ]
Chern, Yih-Jong [3 ]
Liao, Chun-Kai [3 ]
Hsu, Yu-Jen [3 ]
Tsai, Wen-Sy [3 ]
Hsieh, Pao-Shiu [3 ]
Lin, Yu-Fen [1 ]
Lee, Hsiu-Lan [1 ]
You, Jeng-Fu [3 ]
机构
[1] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Nursing, Taoyuan 33305, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Div Hematol Oncol, Taoyuan 33305, Taiwan
[3] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Surg,Div Colon & Rectal Surg, Taoyuan 33305, Taiwan
关键词
metastatic CRC; mCRC; skin toxicity; survival; anti-EGFR; QUALITY-OF-LIFE; PANITUMUMAB; MANAGEMENT; THERAPY; IMPACT; TRIAL;
D O I
10.3390/cancers15061663
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary treatment for metastatic colorectal cancer (mCRC) consists of targeted therapy and chemotherapy to improve survival. A molecular target drug with an anti-epidermal growth factor receptor (EGFR) antagonist is recommended when the RAS and BRAF genes are normal. About 50-70% of patients using anti-EGFR antagonists will experience skin reactions. Some studies have shown that severe skin reactions caused by anti-EGFR antagonists may be linked to overall survival (OS) and progression-free survival (PFS), but the results are still uncertain. These data of mCRC patients who underwent anti-EGFR therapy between October 2017 and October 2018 were analyzed retrospectively. A total of 111 patients were included in this study. The survival results showed that gender, age, body mass index, primary tumor site, and recurrence did not significantly affect OS and PFS. However, the first-line anti-EGFR inhibitor treatment was significantly associated with OS (p < 0.001) and PFS (p < 0.001). There was no significant difference in the incidence of acne between males and females in grades 1 and 2, while males have a greater risk in grades 3 and 4 than females (20.3 vs. 4.8%; p-value = 0.041). Skin toxicity was not a predictor of anti-EGFR treatment response in this investigation.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Quantitative analysis of the impact of deepness of response on survival time following patients with metastatic colorectal cancer treated by chemotherapy and anti-EGFR monoclonal antibodies.
    Osumi, Hiroki
    Matsusaka, Satoshi
    Suenaga, Mitsukuni
    Wakatsuki, Takeru
    Ogura, Mariko
    Ozaka, Masato
    Shinozaki, Eiji
    Chin, Keisho
    Mizunuma, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies
    Michihiro Yoshida
    Takaya Shimura
    Mikinori Sato
    Masahide Ebi
    Takahiro Nakazawa
    Hiromitsu Takeyama
    Takashi Joh
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 367 - 378
  • [43] Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.
    Mariani, Stefano
    Puzzoni, Marco
    Liscia, Nicole
    Impera, Valentino
    Pretta, Andrea
    Tolu, Simona
    Pireddu, Anna Grazia
    Persano, Mara
    Musio, Francesca
    Donisi, Clelia
    Pinna, Giovanna
    Lai, Eleonora
    Demurtas, Laura
    Ziranu, Pina
    Pusceddu, Valeria
    Pisano, Marina
    Palomba, Grazia
    Casula, Milena
    Palmieri, Giuseppe
    Scartozzi, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
    S. Abdelwahab
    A. Azmy
    H. Abdel-aziz
    H. Salim
    A. Mahmoud
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1487 - 1492
  • [45] Nanofluidic digital PCR for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies
    Azuara, D.
    Santos, C.
    Lopez-Doriga, A.
    Montal, R.
    Sanjuan, X.
    Moreno, V.
    Tabernero, J.
    Montagut, C.
    Salazar, R.
    Capella, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S154 - S155
  • [46] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    Liu, X.
    George, G. C.
    Tsimberidou, A. M.
    Naing, A.
    Wheler, J. J.
    Kopetz, S.
    Fu, S.
    Piha-Paul, S. A.
    Eng, C.
    Falchook, G. S.
    Janku, F.
    Garrett, C.
    Karp, D.
    Kurzrock, R.
    Zinner, R.
    Raghav, K.
    Subbiah, V.
    Hess, K.
    Meric-Bernstam, F.
    Hong, D. S.
    Overman, M. J.
    BMC CANCER, 2015, 15
  • [47] Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
    Rossini, Daniele
    Germani, Marco Maria
    Pagani, Filippo
    Pellino, Antonio
    Dell'Aquila, Emanuela
    Bensi, Maria
    Liscia, Nicole
    Moretto, Roberto
    Boccaccino, Alessandra
    Prisciandaro, Michele
    Manglaviti, Sara
    Schirripa, Marta
    Vivolo, Raffaella
    Scartozzi, Mario
    Santini, Daniele
    Salvatore, Lisa
    Pietrantonio, Filippo
    Loupakis, Fotios
    Falcone, Alfredo
    Cremolini, Chiara
    CLINICAL COLORECTAL CANCER, 2020, 19 (03) : 191 - +
  • [48] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
    Abdelwahab, S.
    Azmy, A.
    Abdel-aziz, H.
    Salim, H.
    Mahmoud, A.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (09) : 1487 - 1492
  • [49] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    X. Liu
    G. C. George
    A. M. Tsimberidou
    A. Naing
    J. J. Wheler
    S. Kopetz
    S. Fu
    S. A. Piha-Paul
    C. Eng
    G. S. Falchook
    F. Janku
    C. Garrett
    D. Karp
    R. Kurzrock
    R. Zinner
    K. Raghav
    V. Subbiah
    K. Hess
    F. Meric-Bernstam
    D. S. Hong
    M. J. Overman
    BMC Cancer, 15
  • [50] Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
    Naoki Takahashi
    Satoru Iwasa
    Hirokazu Taniguchi
    Yusuke Sasaki
    Hirokazu Shoji
    Yoshitaka Honma
    Atsuo Takashima
    Natsuko Okita
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    Yasuhide Yamada
    British Journal of Cancer, 2016, 114 : 1003 - 1011